Stay up to date on the latest oncology and nursing conferences.
Apalutamide Elicits PSA Response, Lowers Progression to Castration Resistant Disease in mCSPC
April 30th 2023Findings from a real-world, retrospective analysis support the use of apalutamide for the prostate-specific antigen reduction among patients with metastatic castration-sensitive prostate cancer.
Hyperthermic Intraperitoneal Chemotherapy is Not Associated With Worse HRQOL in Ovarian Cancer
April 2nd 2023Patients with ovarian cancer who received hyperthermic intraperitoneal chemotherapy with cytoreductive surgery did not experience worse health-related quality of life, according to investigators.
Arash Rezazadeh Kalebasty Discusses Darolutamide Combination Safety in the ARASENS Study
March 31st 2023Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.